Maxim CFA - Avalo Therapeutics VP Relations
| AVTX Stock | USD 10.13 0.48 4.97% |
Insider
Maxim CFA is VP Relations of Avalo Therapeutics
| Address | 540 Gaither Road, Rockville, MD, United States, 20850 |
| Phone | 410-522-8707 |
| Web | https://www.avalotx.com |
Avalo Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.3064) % which means that it has lost $0.3064 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4252) %, meaning that it created substantial loss on money invested by shareholders. Avalo Therapeutics' management efficiency ratios could be used to measure how well Avalo Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -3.16 in 2024. Return On Capital Employed is likely to drop to -1.5 in 2024. At this time, Avalo Therapeutics' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 16.6 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 112 K in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| George Eldridge | Aerovate Therapeutics | 61 | |
| Behrad Derakhshan | Edgewise Therapeutics | 44 | |
| DCPSA FFPM | Bionomics Ltd ADR | N/A | |
| Kerry Whalen | Cullinan Oncology LLC | N/A | |
| Jesper Olsen | Acrivon Therapeutics, Common | N/A | |
| MSc MBA | AnaptysBio | 48 | |
| Scott Anderson | Anebulo Pharmaceuticals | N/A | |
| Rami Elghandour | Arcellx | 45 | |
| Connor MSc | Bionomics Ltd ADR | 36 | |
| Leila MD | Pmv Pharmaceuticals | 61 | |
| Thomas Schwerzmann | Molecular Partners AG | N/A | |
| Jeffrey Trigilio | Cullinan Oncology LLC | 40 | |
| David Mack | Pmv Pharmaceuticals | 62 | |
| Kelly Schick | C4 Therapeutics | 44 | |
| Jason Davis | Virax Biolabs Group | 52 | |
| Kristina Zambouras | C4 Therapeutics | N/A | |
| Michael Pitzner | Molecular Partners AG | N/A | |
| Stephan Jackman | Alzamend Neuro | 48 | |
| Neeraj Teotia | Arcellx | 49 | |
| Jennifer Michaelson | Cullinan Oncology LLC | 57 | |
| Dennis Mulroy | AnaptysBio | 69 | |
Management Performance
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.31 |
Avalo Therapeutics Leadership Team
Elected by the shareholders, the Avalo Therapeutics' board of directors comprises two types of representatives: Avalo Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Avalo. The board's role is to monitor Avalo Therapeutics' management team and ensure that shareholders' interests are well served. Avalo Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Avalo Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Blake MD, Scientific Advisor | ||
| Barbara Slusher, Founder Board | ||
| Maxim CFA, VP Relations | ||
| Christopher CPA, CFO relations | ||
| Garry MD, President Board | ||
| Stephen Thomas, VP Discovery | ||
| Christopher Sullivan, Chief Officer | ||
| Colleen Matkowski, Senior Assurance | ||
| Lisa Hegg, Corporate Management | ||
| Solomon MD, Founder Board | ||
| MPH JD, Chief Officer | ||
| Dino Miano, Senior Operations | ||
| MD FACR, Chief Officer |
Avalo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Avalo Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.31 | ||||
| Operating Margin | (51.65) % | ||||
| Current Valuation | 24.69 M | ||||
| Shares Outstanding | 10.46 M | ||||
| Shares Owned By Insiders | 5.86 % | ||||
| Shares Owned By Institutions | 65.20 % | ||||
| Number Of Shares Shorted | 10.06 K | ||||
| Price To Book | 5.03 X | ||||
| Price To Sales | 129.26 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Avalo Stock Analysis
When running Avalo Therapeutics' price analysis, check to measure Avalo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avalo Therapeutics is operating at the current time. Most of Avalo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Avalo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avalo Therapeutics' price. Additionally, you may evaluate how the addition of Avalo Therapeutics to your portfolios can decrease your overall portfolio volatility.